{"nctId":"NCT04622735","briefTitle":"Nefopam/Paracetamol Fixed Dose Combination in Acute Pain After Impacted Third Molar Extraction","startDateStruct":{"date":"2020-02-22","type":"ACTUAL"},"conditions":["Acute Pain"],"count":321,"armGroups":[{"label":"FDC nefopam hydrochloride 30 mg / paracetamol 500 mg (X2)","type":"EXPERIMENTAL","interventionNames":["Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2"]},{"label":"Paracetamol 500 mg (X2)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Paracetamol 500 Mg Oral Tablet X2"]},{"label":"Nefopam hydrochloride 30 mg (X2)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nefopam HCl 30 MG Oral Tablet X2"]}],"interventions":[{"name":"nefopam hydrochloride 30mg / paracetamol 500mg X2","otherNames":[]},{"name":"Paracetamol 500 Mg Oral Tablet X2","otherNames":["Acetaminophen"]},{"name":"Nefopam HCl 30 MG Oral Tablet X2","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* Male and female patient aged from 18 years up to 65 years,\n* Patient scheduled to undergo the surgical removal of at least one fully or partially impacted third mandibular molar requiring bone removal under short-acting local anaesthetic (mepivacaine or lidocaine) with or without vasoconstrictor,\n* Patient weighing \\> 50 kg,\n* Patient who has signed a written informed consent prior to any study-related procedures.\n\nAdditional inclusion criteria after surgery (randomization):\n\n1. Patient experiencing moderate to severe pain within 4 hours after the dental extraction, defined by a baseline pain intensity Visual Analogic Scale (VAS) score ≥ 50 mm,\n2. Third molar extraction(s) completed without any immediate complication, that in the opinion of the investigator, would interfere with the study conduct and/or assessments (e.g., suspected neurosensory complication, incomplete removal of tooth)\n\nMain Exclusion Criteria:\n\n* Patient treated by analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) within 3 days preceding the day of randomization or within 5 times the elimination half-life whichever the longest,\n* Woman with positive results on a urine pregnancy test or breastfeeding woman or woman of childbearing potential without an effective contraception,\n* Patient with a history of convulsive disorders,\n* Patient taking mono-amine-oxidase (MAO) inhibitors (including but not limited to selegiline, isocarboxazid, tranylcypromine, phenelzine…),\n* Patient with an abnormal cardiac condition: medically significant disorders of cardiac rate and/or rhythm,\n* Patient with known anaemia,\n* Patient with known pulmonary disease,\n* Patient with known active gastric or duodenal ulcer or a history of recurrent gastrointestinal ulcer/bleeding,\n* Patient with known glaucoma,\n* Patients with a prostatic hyperplasia or urinary retention,\n* Patient with current or chronic history of liver disease, or known hepatic or biliary abnormalities,\n* Patient with a current or chronic history of severe renal impairment (glomerular filtration below 30 mL/min),","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ranked Endpoints : 1. Sum of Pain Intensity Differences at 6 Hours (SPID0-6h)","description":"Pain intensity difference (PID) will be calculated using the score of pain intensity assessed by the patient at defined time points (T30, T45, T60, T90, T120, T150, T180, T240, T300, T360 min,) after the first Investigational Medicinal Product (IMP) intake and/or right before first intake of rescue medication using a 100-mm Visual Analogic Scale (VAS) compared to baseline.\n\nCalculation: Sum of Pain intensity difference (SPID) is the time-weighted summary measure of the total area under the pain intensity difference (PID) curve that integrates serial assessments of pain during x times after the first Investigational Medicinal Product\n\nSPID0-6h= SPID0-30min+SPID30min-45min+SPID45min-1h+SPID1h-1h30+SPID1h30-2h+SPID2h-2h30+SPID2h30-3h+SPID3h-4h+SPID4h-5h+SPID5h-6h With: SPIDTime1-Time2 = (PID Theoretical Time1 + PID Theoretical Time2) \\* (Theoretical Time2- Theoretical Time1) / 2 SPID min 0-6h = 0 SPID max 0-6h = 36000 The lower score mean a better score","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8955.4","spread":"8751.8"},{"groupId":"OG001","value":"8458.0","spread":"8831.7"},{"groupId":"OG002","value":"5290.7","spread":"9109.3"}]}]}]},{"type":"PRIMARY","title":"Total Pain Relief at 6 Hours (TOTPAR0-6h)","description":"Pain Relief will be assessed by the patient at defined time points (T30, T45, T60, T90, T120, T150, T180, T240, T300, T360 min) after the first IMP intake and/or right before first intake of rescue medication using a 5-point verbal rating scale (VRS).\n\nCalculation: TOTPAR is the time-weighted summary measure of the total area under the pain release difference curve that integrates serial assessments of pain release during x times after the first Investigational Medicinal Product TOTPAR0-6h=TOTPAR0-30min+TOTPAR30min-45min+TOTPAR45min-1h+TOTPAR1h-1h30+TOTPAR1h30-2h+TOTPAR2h-2h30+TOTPAR2h30-3h+ TOTPAR 3h-4h+ TOTPAR 4h-5h+ TOTPAR 5h-6h With: TOTPARTime1-Time2 = (PAR Time1 + PAR Time2) \\* (Time2-Time1) / 2 And with the score of pain relief at T0 = 0 (\"none\") TOTPAR min 0-6h = 0 TOTPAR max 0-6h = 1800 The higher score mean a better outcome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"610.6","spread":"434.5"},{"groupId":"OG001","value":"602.2","spread":"383.6"},{"groupId":"OG002","value":"461.4","spread":"384.5"}]}]}]},{"type":"PRIMARY","title":"Proportion of Responder Patients","description":"A responder patient is a subject who achieves a reduction of 50% of pain intensity compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"35","spread":null}]}]}]},{"type":"PRIMARY","title":"The Patient's Global Impression of Change (PGIC) Questionnaire","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"The Onset of Pain Relief","description":"Score of pain intensity will be assessed by the patient at defined time points (T30, T45, T60, T90, T120, T150, T180, T240, T300, T360 min). The time point of the first assessment obtaining a score ≤ 30 mm will be retained as time score of onset of pain relief.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"74","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Pain Relief at 1 Hour (TOTPAR0-1h), 2 Hours (TOTPAR0-2h), 3 Hours (TOTPAR0-3h), and 4 Hours (TOTPAR0-4h)","description":"Pain relief (PAR) will be assessed by the patient at defined time points (T30, T45, T60, T90, T120, T150, T180, T240 min) after the first IMP intake and/or right before first intake of rescue medication using a 5-point verbal rating scale\n\nCalculation: TOTPAR is the time-weighted summary measure of the total area under the pain release difference curve that integrates serial assessments of pain release during x times after the first Investigational Medicinal Product TOTPAR0-6h=TOTPAR0-30min+TOTPAR30min-45min+TOTPAR45min-1h+TOTPAR1h-1h30+TOTPAR1h30-2h+TOTPAR2h-2h30+TOTPAR2h30-3h+ TOTPAR 3h-4h+ TOTPAR 4h-5h+ TOTPAR 5h-6h With: TOTPARTime1-Time2 = (PAR Time1 + PAR Time2) \\* (Time2-Time1) / 2 And with the score of pain relief at T0 = 0 (\"none\") TOTPAR min 0-any time = 0 TOTPAR max 0-1h = 300 ; TOTPAR max 0-2h = 600 ;TOTPAR max 0-3h = 900 ;TOTPAR max 0-4h = 1200 ; The higher score mean a better outcome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.2","spread":"54.2"},{"groupId":"OG001","value":"69.4","spread":"49.5"},{"groupId":"OG002","value":"49.7","spread":"47.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"170.0","spread":"130.6"},{"groupId":"OG001","value":"183.0","spread":"115.7"},{"groupId":"OG002","value":"133.2","spread":"116.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"285.4","spread":"210.5"},{"groupId":"OG001","value":"300.8","spread":"184.7"},{"groupId":"OG002","value":"216.3","spread":"185.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"399.7","spread":"288.4"},{"groupId":"OG001","value":"412.2","spread":"252.2"},{"groupId":"OG002","value":"298.4","spread":"254.4"}]}]}]},{"type":"SECONDARY","title":"Sum of Pain Intensity Differences at 1 Hour (SPID0-1h), 2 Hours (SPID0-2h), 3 Hours (SPID0-3h), and 4 Hours (SPID0-4h)","description":"PID will be calculated using the score of pain intensity assessed by the patient at defined time points (T30, T45, T60, T90, T120, T150, T180, T240 min) after the first IMP intake and/or right before first intake of rescue medication using a 100-mm VAS compared to baseline.\n\nCalculation: SPID is the time-weighted summary measure of the total area under the pain intensity difference curve that integrates serial assessments of pain during x times after the first IMP\n\nSPID0-4h= SPID0-30min+SPID30min-45min+SPID45min-1h+SPID1h-1h30+SPID1h30-2h+SPID2h-2h30+SPID2h30-3h+SPID3h-4h With: SPIDTime1-Time2 = (PID Theoretical Time1 + PID Theoretical Time2) \\* (Theoretical Time2- Theoretical Time1) / 2 SPID min 0-any time = 0 SPID max 0-1h = 6000 ; SPID max 0-2h = 12000; SPID max 0-3h = 18000; SPID max 0-4h = 24000 The lower score mean a better score","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"743.7","spread":"1075.2"},{"groupId":"OG001","value":"809.5","spread":"1017.3"},{"groupId":"OG002","value":"506.4","spread":"1042.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2405.9","spread":"2553.0"},{"groupId":"OG001","value":"2418.4","spread":"2469.2"},{"groupId":"OG002","value":"1487.2","spread":"2723.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4281.3","spread":"4071.1"},{"groupId":"OG001","value":"4128.8","spread":"4022.0"},{"groupId":"OG002","value":"2486.8","spread":"4425.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6039.8","spread":"5636.4"},{"groupId":"OG001","value":"5786.0","spread":"5639.1"},{"groupId":"OG002","value":"3467.2","spread":"6054.1"}]}]}]},{"type":"SECONDARY","title":"The Pain Intensity Differences (PID) Assessment","description":"PID will be calculated using the scores of pain intensity (VAS) at each time point compared to baseline.\n\nPID30min = VAS of pain intensity 30min - VAS of pain intensity baseline PID min = 0 / PID max = 100 A higher PID is a better outcome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.4","spread":"22.6"},{"groupId":"OG001","value":"-14.8","spread":"22.3"},{"groupId":"OG002","value":"-8.6","spread":"20.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.1","spread":"27"},{"groupId":"OG001","value":"-19.6","spread":"24.6"},{"groupId":"OG002","value":"-12.7","spread":"25.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.2","spread":"30.2"},{"groupId":"OG001","value":"-18.0","spread":"31.1"},{"groupId":"OG002","value":"-14.6","spread":"29.2"}]}]}]},{"type":"SECONDARY","title":"Proportion of Responder Patients.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to the Second Investigational Medicinal Product (IMP) Intake","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"438.5","spread":null},{"groupId":"OG001","value":"429.0","spread":null},{"groupId":"OG002","value":"387.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Participant Having Taken a Rescue Analgesic Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Sum of Pain Intensity Differences","description":"Pain Intensity Difference (PID) will be calculated using the score of pain intensity assessed by the patient at defined time points using a 100-mm visual Analog Scale (VAS) compared to baseline.\n\nCalculation: Sum of Pain Intensity Difference (SPID) is the time-weighted summary measure of the total area under the pain intensity difference curve that integrates serial assessments of pain during x times after the first Investigational Medicinal Product\n\nWith: SPIDTime1-Time2 = (VAS Theoretical Time1 + VAS Theoretical Time2) \\* (Theoretical Time2- Theoretical Time1) / 2 SPID min 0-any time = 0 SPID max 0-day 1 = 144000 ; SPID max 0-day 2 = 288000 ; SPID max 0-day 3 = 432000 ; SPID max 0-day 4 = 576000 ; SPID max 0-day 5 = 720000 ; The lower score means a better outcome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23306.5","spread":"23707.8"},{"groupId":"OG001","value":"22173.7","spread":"25105.0"},{"groupId":"OG002","value":"19910.3","spread":"28416.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48792.4","spread":"48167.2"},{"groupId":"OG001","value":"44604.7","spread":"48227.7"},{"groupId":"OG002","value":"42972.1","spread":"52821.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70094.2","spread":"70059.9"},{"groupId":"OG001","value":"68351.5","spread":"71111.0"},{"groupId":"OG002","value":"61347.0","spread":"75669.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84261.6","spread":"84118.3"},{"groupId":"OG001","value":"84781.0","spread":"90576.9"},{"groupId":"OG002","value":"73960.7","spread":"96674.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92644.0","spread":"96128.8"},{"groupId":"OG001","value":"96134.2","spread":"107774.7"},{"groupId":"OG002","value":"78299.5","spread":"106041.1"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Having Taken a Rescue Analgesic Treatment Throughout the Study.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"The Total Dose of Rescue Medication Taken.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"5.2"},{"groupId":"OG001","value":"7.3","spread":"4.5"},{"groupId":"OG002","value":"6.0","spread":"4.0"}]}]}]},{"type":"SECONDARY","title":"Mean Duration Under Rescue Medication Over the 5 Days.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.9","spread":"51.5"},{"groupId":"OG001","value":"99.4","spread":"144.5"},{"groupId":"OG002","value":"61.9","spread":"42.2"}]}]}]},{"type":"SECONDARY","title":"Number of Investigational Medicinal Product (IMP) Intakes","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":"4.5"},{"groupId":"OG001","value":"5.8","spread":"4.2"},{"groupId":"OG002","value":"5.1","spread":"3.6"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Impression of Change (PGIC) Score","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Occurrence of Adverse Events (Serious and Non-serious Adverse Events).","description":"= Number of Events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"35","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":107},"commonTop":["NAUSEA","HEADACHE","DIZZINESS","SOMNOLENCE","PYREXIA"]}}}